1. Home
  2. CELH vs RGEN Comparison

CELH vs RGEN Comparison

Compare CELH & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celsius Holdings Inc.

CELH

Celsius Holdings Inc.

HOLD

Current Price

$45.60

Market Cap

10.1B

ML Signal

HOLD

Logo Repligen Corporation

RGEN

Repligen Corporation

HOLD

Current Price

$165.56

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CELH
RGEN
Founded
2004
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Medical/Dental Instruments
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
8.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CELH
RGEN
Price
$45.60
$165.56
Analyst Decision
Strong Buy
Buy
Analyst Count
18
10
Target Price
$63.41
$174.90
AVG Volume (30 Days)
5.1M
618.1K
Earning Date
11-06-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.13
0.03
Revenue
$2,125,838,000.00
$707,890,000.00
Revenue This Year
$82.94
$17.84
Revenue Next Year
$32.22
$12.44
P/E Ratio
$377.27
$5,383.25
Revenue Growth
55.07
11.74
52 Week Low
$21.10
$102.97
52 Week High
$66.74
$182.52

Technical Indicators

Market Signals
Indicator
CELH
RGEN
Relative Strength Index (RSI) 54.79 57.69
Support Level $44.15 $156.01
Resistance Level $45.45 $167.74
Average True Range (ATR) 1.60 4.27
MACD 0.73 0.04
Stochastic Oscillator 90.42 81.59

Price Performance

Historical Comparison
CELH
RGEN

About CELH Celsius Holdings Inc.

Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Share on Social Networks: